[{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Not Applicable"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"IRISYS, LLC \/ BioCorRx","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LLC \/ BioCorRx"},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Marie Tooth Association \/ Pharnext"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opoid mu\/kappa\/delta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cytocom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ Not Applicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aardvark Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute of Drug Abuse"},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Soin Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Neuroscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Soin Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soin Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Not Applicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"Societal CDMO \/ BioCorRx","highestDevelopmentStatusID":"6","companyTruncated":"Societal CDMO \/ BioCorRx"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ NIH"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institutes Of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institutes Of Health"},{"orgOrder":0,"company":"Delpor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delpor \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"GABA B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Neovacs"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Naltrexone Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Naltrexone Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Naltrexone Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Naltrexone Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"Soin Therapeutics","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Naltrexone","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Soin Therapeutics \/ JanOne","highestDevelopmentStatusID":"4","companyTruncated":"Soin Therapeutics \/ JanOne"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pellet","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Not Applicable"},{"orgOrder":0,"company":"Immgenuity","sponsor":"Biostax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"IMTVO14","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immgenuity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immgenuity \/ Biostax","highestDevelopmentStatusID":"4","companyTruncated":"Immgenuity \/ Biostax"},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Inventage Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inventage Lab \/ Not Applicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"}]
Find Clinical Drug Pipeline Developments & Deals for Naltrexone
Details :
BioCorRx will focus funding on clinical development of BICX104 (naltrexone) in combination with Bupropion, currently in preclinical studies for methamphetamine use disorder.
Details :
IVL3004 (naltrexone) is an opiod antagonist. It is a one-month long-acting injection based on company's IVL-DrugFluidic® technology. It is designed to treat opioid addiction.
Details :
The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal™ and JKB-122 both independently and together to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achi...
Details :
The submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
Details :
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Details :
Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Details :
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Details :
Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Details :
Naltrexone is an opioid antagonist, primarily used to manage alcohol and or opioid use disorder by reducing cravings and feelings of euphoria associated with substance abuse disorder.
Details :
Naltrexone treatments work to block mu-opioid receptors when administered orally or through injection. The effective blockade of delta‐opioid receptors requires much higher plasma naltrexone concentrations than is achieved by currently approved naltrex...
Reset All
